Fuller & Thaler Asset Management Inc. Decreases Holdings in Integra LifeSciences Holdings Co. (NASDAQ:IART)

Fuller & Thaler Asset Management Inc. lowered its stake in shares of Integra LifeSciences Holdings Co. (NASDAQ:IART - Free Report) by 0.9% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,932,279 shares of the life sciences company's stock after selling 35,283 shares during the period. Fuller & Thaler Asset Management Inc. owned about 5.10% of Integra LifeSciences worth $89,184,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also recently modified their holdings of the company. Price T Rowe Associates Inc. MD raised its holdings in shares of Integra LifeSciences by 10.4% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 47,090 shares of the life sciences company's stock valued at $1,069,000 after acquiring an additional 4,452 shares during the last quarter. State of Tennessee Department of Treasury raised its position in shares of Integra LifeSciences by 34.7% in the fourth quarter. State of Tennessee Department of Treasury now owns 23,381 shares of the life sciences company's stock valued at $530,000 after buying an additional 6,026 shares during the last quarter. Tower Research Capital LLC TRC lifted its stake in shares of Integra LifeSciences by 388.0% in the fourth quarter. Tower Research Capital LLC TRC now owns 18,847 shares of the life sciences company's stock worth $427,000 after buying an additional 14,985 shares in the last quarter. MetLife Investment Management LLC boosted its position in Integra LifeSciences by 5.3% during the fourth quarter. MetLife Investment Management LLC now owns 41,749 shares of the life sciences company's stock worth $947,000 after acquiring an additional 2,111 shares during the last quarter. Finally, Capital Research Global Investors grew its stake in Integra LifeSciences by 7.4% during the 4th quarter. Capital Research Global Investors now owns 1,400,559 shares of the life sciences company's stock valued at $31,765,000 after acquiring an additional 95,944 shares in the last quarter. Institutional investors and hedge funds own 84.78% of the company's stock.

Integra LifeSciences Trading Up 3.2 %

NASDAQ IART opened at $15.67 on Wednesday. The company has a debt-to-equity ratio of 0.79, a current ratio of 1.20 and a quick ratio of 0.73. The stock has a market capitalization of $1.21 billion, a P/E ratio of -174.09, a PEG ratio of 0.73 and a beta of 1.24. The firm's 50-day moving average is $20.95 and its two-hundred day moving average is $22.23. Integra LifeSciences Holdings Co. has a 12 month low of $14.45 and a 12 month high of $32.66.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last posted its quarterly earnings data on Tuesday, February 25th. The life sciences company reported $0.97 earnings per share for the quarter, topping analysts' consensus estimates of $0.85 by $0.12. The firm had revenue of $442.65 million during the quarter, compared to analysts' expectations of $445.15 million. Integra LifeSciences had a negative net margin of 0.42% and a positive return on equity of 12.35%. The firm's quarterly revenue was up 11.5% on a year-over-year basis. During the same quarter last year, the company posted $0.89 EPS. On average, sell-side analysts anticipate that Integra LifeSciences Holdings Co. will post 2.45 earnings per share for the current year.

Analysts Set New Price Targets

Several research analysts have recently weighed in on IART shares. Argus upgraded Integra LifeSciences from a "hold" rating to a "buy" rating in a report on Monday, March 31st. Truist Financial cut their target price on Integra LifeSciences from $26.00 to $19.00 and set a "hold" rating for the company in a research note on Friday, April 11th. Three research analysts have rated the stock with a sell rating, five have assigned a hold rating and two have issued a buy rating to the stock. According to MarketBeat, Integra LifeSciences presently has an average rating of "Hold" and an average price target of $22.71.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.